Risk Factors for Breakthrough Pneumocystis carinii Pneumonia on Aerosol Pentamidine Prophylaxis

Canadian Respiratory Journal. 1995;2(1):49-54 DOI 10.1155/1995/948507

 

Journal Homepage

Journal Title: Canadian Respiratory Journal

ISSN: 1198-2241 (Print); 1916-7245 (Online)

Publisher: Hindawi Limited

LCC Subject Category: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system

Country of publisher: United Kingdom

Language of fulltext: English

Full-text formats available: PDF, HTML, ePUB, XML

 

AUTHORS

RA McIvor (Department of Medicine, The Wellesley and Sunnybrook Hospitals, University of Toronto, and The Toronto Central Aerosol Pentamidine Clinic, Toronto, Ontario, Canada)
AR Rachlis (Department of Medicine, The Wellesley and Sunnybrook Hospitals, University of Toronto, and The Toronto Central Aerosol Pentamidine Clinic, Toronto, Ontario, Canada)
P Berger (Department of Medicine, The Wellesley and Sunnybrook Hospitals, University of Toronto, and The Toronto Central Aerosol Pentamidine Clinic, Toronto, Ontario, Canada)
LR Lee Pack (Department of Medicine, The Wellesley and Sunnybrook Hospitals, University of Toronto, and The Toronto Central Aerosol Pentamidine Clinic, Toronto, Ontario, Canada)
Charles K Chan (Department of Medicine, The Wellesley and Sunnybrook Hospitals, University of Toronto, and The Toronto Central Aerosol Pentamidine Clinic, Toronto, Ontario, Canada)

EDITORIAL INFORMATION

Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 38 weeks

 

Abstract | Full Text

OBJECTIVE: To identify baseline characteristics of human immunodeficiency virus (HIV)-infected individuals on aerosol pentamidine for Pneumocystis carinii prophylaxis that are predictive of subsequent breakthrough Pneumocystis carinii pneumonia (PCP).